OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer Research is 61. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Abstract P1-13-04: Evaluation of the impact Vitamin D and Calcium supplementation on bone mineral density in breast cancer patients using or not taking Aromatase Inhibitors: 5-year follow-up	477
Abstract P4-12-09: Implications of protocol modifications and treatment delays for breast cancer patient experiences during Covid-19	191
Abstract P2-12-23: Changes in 18F-FDG-PET uptake after the first course of DTX reflect response to preoperative chemotherapy and prognosis in breast cancer	189
Abstract OT1-05-01: Glycoprotein 88 (GP-88) serum levels as a marker of response to therapy in patients with metastatic breast cancer	181
Abstract P3-19-16: Impact of targeted intraoperative (TARGIT-IORT) tumor bed boost during breast conserving surgery for early breast cancer on breast cancer associated and non-breast cancer associated	158
Abstract PD13-07: Activity and biomarker analyses from a phase Ia/b study of giredestrant (GDC-9545; G) with or without palbociclib (palbo) in patients with estrogen receptor-positive, HER2-negative l	154
Abstract P3-20-09: Surgery vs radiation therapy as the first stage treatment in patients with locally advanced breast cancer with incomplete clinical response	146
Abstract P5-08-02: MORAb-202, an antibody-drug-conjugate (ADC) targeting folate receptor alpha (FRα), exhibits durable anti-tumor efficacy in PDx models of TNBC	140
Abstract P3-12-20: Outcomes of patients with pathologic complete response following neoadjuvant HER2-targeted therapy in patients with HER2+ early stage breast cancer	133
Abstract P4-01-16: Overcome chemoresistance of triple-negative breast cancer by inhibiting the RNA-binding protein HuR	127
Abstract PD3-03: EZH2 T367 phosphorylation activates p38 signaling through lysine methylation to promote breast cancer progression	125
Abstract OT2-21-01: A randomized, multicenter pragmatic trial comparing bone pain from a single dose of pegfilgrastim to 5 doses of daily filgrastim in breast cancer patients receiving neoadjuvant/adj	119
Abstract P4-11-16: Feasibility and patient satisfaction with a smartphone application to improve medication adherence among patients with breast cancer	118
Abstract P4-05-09: Clinicopathologic characteristics and molecular profiling of HER2-low breast cancer: A single academic institution experience	117
Abstract P3-18-14: Assessment of quality of life and objective cosmetic outcome of breast conserving surgery with or without latissimus dorsi mini-flap in breast cancer	114
Abstract P4-10-10: Effectiveness and feasibility of exercise-oncology programs in breast cancer patients using new technologies adapted to the COVID 19 new normality	113
Abstract P1-08-09: High mid-treatment RNA disruption in patients with HER2-negative breast cancer predicts survival benefit after neoadjuvant chemotherapy	112
Abstract P1-07-01: Real time detection of ESR1 mutation in blood by droplet digital PCR in the PADA-1 trial: Feasibility and cross-validation with NGS	112
Abstract P1-08-07: Prediction model of the response of neoadjuvant chemotherapy and long term survival according to multi-omic profiling in cooperation with clinicopathologic features in patients with	105
Abstract P4-11-05: How to stay sexually active and sexually well-functioning after breast cancer - Reporting from the SWEET study	105
Abstract P1-06-01: Insights from rapid autopsy shed light on mechanisms of cancer dissemination in metastatic breast cancer	105
Abstract ES8-2: Can radiation replace ALND after positive SLNB?	100
Abstract P5-14-10: Examining inequities associated with incarceration among patients with breast cancer	97
Abstract GS2-01: Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2− breast	95
Abstract PD4-03: Characterization of HER2 amplification in the cerebrospinal fluid of patients with Leptomeningeal Disease in stage IV patients with breast cancer	94

Abstract P5-13-17: PD-L1 expression in breast to brain metastases	91
Abstract P2-15-01: Conversion from luminal to normal intrinsic subtype by PAM50 after neoadjuvant endocrine therapy is associate with biomarkers of good prognosis in luminal breast cancer	88
Editor's Note: p38 Mitogen-Activated Protein Kinase-Driven MAPKAPK2 Regulates Invasion of Bladder Cancer by Modulation of MMP-2 and MMP-9 Activity	86
Abstract PO-119: DFMO mediated improvement in survival of an orthotopic model of pancreatic cancer is associated with modulating immune suppression in the tumor microenvironment	86
Hyperactive Dendritc Cells Redirect Aged Antitumor Immunity	81
Abstract P1-18-17: Phase I study of cfi-402257, an oral ttk inhibitor, in patients with advanced solid tumors with breast cancer expansion cohorts	80
Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma	78
Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing NRAS-Mutant Melanoma to MEK Inhibitors	77
Polypharmacologic Reprogramming of Tumor-Associated Macrophages toward an Inflammatory Phenotype	76
Abstract P5-01-03: Mouse-intraductal (MIND): An in vivo model for studying the underlying mechanisms of DCIS malignancy	75
Abstract P5-13-12: Immune signatures and MammaPrint (ultra) high risk class (MP2) as predictors of response to pembrolizumab combined with the TLR9 agonist SD101 in the neoadjuvant I-SPY 2 TRIAL	75
Comprehensive Proteogenomic Profiling Reveals the Molecular Characteristics of Colorectal Cancer at Distinct Stages of Progression	73
Abstract 7218: Preventive use of trilaciclib in Chinese patient with extensive-stage small cell lung cancer (ES-SCLC) receiving chemotherapy: A multi-center, single-arm, observational real-world study	73
Bcl-xL Enforces a Slow-Cycling State Necessary for Survival in the Nutrient-Deprived Microenvironment of Pancreatic Cancer	73
Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity	72
MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages	72
Liver Colonization by Colorectal Cancer Metastases Requires YAP-Controlled Plasticity at the Micrometastatic Stage	71
SMARCA4 Inhibits Breast Cancer Progression and Metastasis through RHOA Suppression	71
Fam20C Regulates Bone Resorption and Breast Cancer Bone Metastasis through Osteopontin and BMP4	71
A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants	70
A Genetic Locus within the FMN1/GREM1 Gene Region Interacts with Body Mass Index in Colorectal Cancer Risk	70
Abstract 4686: Efficacy and safety of efbemalenograstim alfa as primary prophylaxisfor concurrent chemo-radiotherapy induced neutropenia	69
Abstract CT035: Pharmacokinetics (PK), safety, and tolerability of pembrolizumab with berahyaluronidase alfa administered subcutaneously Q3W in participants with advanced melanoma	68
Mutant KRAS Mediates circARFGEF2 Biogenesis to Promote Lymphatic Metastasis of Pancreatic Ductal Adenocarcinoma	68
TRAF4 Maintains Deubiquitination of Caveolin-1 to Drive Glioblastoma Stemness and Temozolomide Resistance	67
Abstract 2074: MALDI-ICC: a new tool for high-plex, multiomic profiling of single cells for cancer research and cancer therapy	66
Abstract 1273: Advancing precision oncology: Development and utilization of breast cancer PDX models for in vivo drug discovery	65
Abstract 3727: Physical activity patters according to demographic, social, and clinical correlates among breast cancer survivors	65
Abstract 1913: Cystic fluid acetylated polyamines predict risk of malignancy of intraductal papillary mucinous neoplasms of the pancreas	65
Abstract 3731: The role of dietary patterns and microbiome composition in colorectal cancer survival: The ColoCare Study	65
Abstract 1320: Nanotopographical cues enhance glioblastoma migration: Harnessing biomimetic matrices and machine learning to uncover cancer invasion	64
Abstract 3688: Correlation between natural killer cell sensitivity and epithelial mesenchymal transition morphology: A cell morphology based screening for NK cell susceptible tumor cells	64
Abstract 3371: Gene deletions in estrogen receptor positive HER2-negative breast cancer are associated with worse outcome than predicted by diagnostic-grade gene expression assays	63
Abstract 294: TFEB nuclear persistence predicts sensitivity to lysosomal inhibition in therapy-induced senescent thyroid cancer cells	63
Abstract 1124: Mining the Kras-p53 mutational interface for synthetic lethality (SL) in pancreatic adenocarcinoma (PA)	62
Abstract 3655: Leveraging alternative AIML technologies to identify predictive biomarkers for chemotherapy selection: An analysis of the COMPASS trial evaluating chemotherapy response in advanced PDAC	62
Abstract 1510: Glutathione-oxidation of ovarian tumor deubiquitinase-1 promotes lung adenocarcinoma survival through stabilizing system xc-	61
Abstract 47: Optimizing in vivo establishment of hormone receptor-positive breast cancer patient-derived xenografts for therapeutic assessment	61
Abstract 2873: Preclinical development of SMP-656: An eribulin-SuperHydraTM linker based ADC	61
Abstract 424: Chromosomal instability leads to EGFR-TKI refractoriness via cGAS-STING activation in EGFR-mutated non-small cell lung cancer	61